FINNENCE ▪ THE WIRE FILE
THE WIRE · № 64858
News■ Unclear/unknown
SereNeuro Therapeutics Closes Oversubscribed Pre-Seed Financing to Advance Non-Opioid Pain Pipeline
KINDNews
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN2026-10-05 11:00 UTC
LAST UPDATE2026-10-05 11:00 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
Pre-seed biotech financing for a preclinical pain program is private and years from any revenue.
Early biotech funding, no public-market impact
CATALYST TO WATCH
IND filing or partnership announcement
MAIN RISK
Preclinical failure risk is very high
FULL DISPATCH
Lead program SN101, a first-in-class non-opioid iPSC-derived therapy for chronic joint pain, moves toward IND-enabling studies BALTIMORE and PHOENIX, Oct. 5, 2026 /PRNewswire/ -- SereNeuro Therapeutics, a preclinical-stage biotechnology company developing non-opioid therapies for pain,...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
Trex Bio Expects IPO Price Between $14.00-$16 Per Share2026-10-05 10:36 UTC
Trex Bio Expects IPO Price Between $14.00-$16 Per Share2026-10-05 10:36 UTC
→CORRELATIONshares Healthcare
TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology2026-10-05 11:45 UTC
TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology2026-10-05 11:45 UTC
→CORRELATIONshares Healthcare
Lilly to present new data across its dermatology portfolio with 21 presentations at Fall Clinical 2026, in pursuit of advancing care for chronic skin conditions2026-10-05 11:50 UTC
Lilly to present new data across its dermatology portfolio with 21 presentations at Fall Clinical 2026, in pursuit of advancing care for chronic skin conditions2026-10-05 11:50 UTC
←CORRELATIONshares Healthcare
AnnJi Pharmaceutical Advances AJ201 into Pivotal Phase 3 ROMA-KD Trial for Spinal and Bulbar Muscular Atrophy (SBMA)2026-10-05 04:30 UTC
AnnJi Pharmaceutical Advances AJ201 into Pivotal Phase 3 ROMA-KD Trial for Spinal and Bulbar Muscular Atrophy (SBMA)2026-10-05 04:30 UTC
←CORRELATIONshares Healthcare
Symphony™ Randomized Controlled Trial Demonstrates Significantly Improved Healing of Diabetic Foot Ulcers2026-10-05 04:46 UTC
Symphony™ Randomized Controlled Trial Demonstrates Significantly Improved Healing of Diabetic Foot Ulcers2026-10-05 04:46 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.